Three portfolio companies of Maxwell Biotech Group will take part in the Russian Cancer Congress

From 13 to 15 November 2012, the World Trade Center, Moscow, will host the XVI Russian Cancer Congress featuring expositions of the largest pharmaceutical and biotechnology companies in the Russian cancer market.

The event will be attended by Skolkovo Biomedical Cluster resident companies, including OncoMax, Metamax and Osteros Biomedica, backed by Maxwell Biotech Venture Fund, a portfolio fund of JSC "RVC", the Russian government-backed vehicle to boost high tech industry growth. The MBG portfolio companies will present their cancer pipelines with novel drug candidates, including OM-RCA-01, a humanized monoclonal antibody for kidney cancer treatment (OncoMax), MM-D37K, a chimeric peptide to treat cancer of gastrointestinal localizations ( Metamax), and MBC-11, a small molecule targeted agent to treat cancer induced bone lesions and bone metastases and primary bone cancer (Osteros Biomedica).

The company representatives (OncoMax, Metamax and Osteros Biomedica) will be able to provide professional details on the pipeline agents, including mechanisms of action and prospective advantages at the booth of Maxwell Biotech Group in the Congress Hall of the World Trade Center, Moscow.


Анна Зеленкова,
PR директор, ООО «Максвелл Биотех Групп»;
Тел: +7 (495) 411-6992

 Исследования осуществляются ООО «ОнкоМакс» при грантовой поддержке Фонда «Сколково».